News

LONDON, UK--(BUSINESS WIRE)--Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting.

London, UK - 16 February 2026 - Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapy for the treatment...

London, UK - November 11, 2025 — Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the...

LONDON, United Kingdom, November 1, 2024 – Prokarium, a biopharmaceutical company developing innovative cancer treatments, today announced the...

LONDON, UK, March 14, 2024 – Prokarium announces they have been awarded a UK Research and Innovation (UKRI) Engineering Biology...

London, UK – February 7, 2024 –  Prokarium, a clinical-stage biopharmaceutical company bioengineering Living Cures through cutting-edge synthetic...

London, UK – November 2, 2023 – Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create...

London, UK February 9, 2023 – Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has...

LONDON, UK and BOSTON, MA — January 9, 2023 — Prokarium, a biopharmaceuticalcompany pioneering the oncology field of...

LONDON, UK – October 19, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...

LONDON, UK – March 2, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...

LONDON, UK – January 26, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...

LONDON, UK – November 11, 2021– Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today...

LONDON, UK – November 2, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...

London / Amsterdam – October 12, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial...

LONDON, UK – October 5, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...

LONDON, UK – July 27, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...

Entervax is a novel bivalent oral vaccine against enteric fever, currently in a phase 1 trial with the...

Industry veteran, Hyam Levitsky, MD, appointed to Prokarium’s Board of Directors – Financing will support the clinical...

Prokarium receives Notice of Allowance for US patent covering Entervax, an oral bivalent vaccine against enteric fever.

Prokarium advances its oncology programme for bladder cancer signing an exclusive option agreement with CHUV.

Prokarium welcomes Hyam Levitsky and David Holden as new advisors.

MHRA accepts a phase I trial with Prokarium's vaccine against enteric fever.

Wellcome Trust funds Prokarium's vaccine against enteric fever.

Prokarium moves offices and laboratories to LBIC.

Prokarium expands its team to develop a new microbial immunotherapy for solid tumours.

Prokarium closes $10 million Series A round to develop thermostable vaccines.